GE Healthcare is an important supplier of medical imaging solutions worldwide, being present in this industry for over 100 years. We started our collaboration in January 2011 and since then we have been constantly expanding the project. The General Electric Healthcare portfolio that we are focusing on is comprised from the following contrast medium brands: Clariscan, Visipaque and Omnipaque.

ACM is a human scale independent French laboratory founded in 2001. As a dermatology specialist, Laboratoire dermatologique ACM develops and markets medicines, cosmetic products, food supplements and medical devices offering innovative solutions for the most commonly encountered consultation reasons. 

Our partnership with ACM started in 2013 and since then we are in top 9 producers on dermo-cosmetic market. 

http://www.magnifiqueskin.ro/

Curtis Health Caps (CHC) is a global CDMO (Contract Development & Manufacturing

Organisation) with over 30 years' experience in the industry.

The company specialises in contract manufacturing of soft gelatin capsules and non-sterile

liquid dosage forms. In addition, CHC offers R&D services. Our cooperation started in 2013 and

applies to brands such as Bobik or Evital.

Cheplapharm is a family-owned pharmaceutical company, headquartered in Germany. Our partnership with Cheplapharm started in 2016.

In Romania, first meet with Teva portfolio was in May 2019. Since then, we have managed at the end of the year 2018 to register the highest brand awareness on Gregal and also, we managed to double the number of patients who were treated with Duoresp. In 2020 Teva Respiratory has 2 products in MagnaPharm portfolio --> Gregal and Duoresp.

https://www.tevapharm.ro/

Lenus Pharma aim to satisfy human expectations. We do not look singularly at the medical components, but analyse the problem in its totality by looking at the whole person, including understanding its physical, nutritional, environmental, emotional, social, spiritual and lifestyle values. All these components are driving and influencing the development of our products. 

The philosophy of the company is to develop innovative products, meeting unmet medical needs, based on evidence-based Medicine. Our strategic partnership with Lenus Pharma started in 2012 with PROfertil, PROfertil female and in 2019 with Menopearl.

https://www.profertil.ro

Labo Cosprophar Suisse, a Swiss trademark registered in 1989, is pursuing the mission of devoting heavy investments to research to find and patent innovative cosmetic products that are highly beneficial for the consumer.

Our partnership started in 2017 with Crescina and Fillerina brands and year by year we strenghted our partnership by introducing new ranges on the local market (Cadu-Crex, Follicular Islands & Fillerina 932).

http://crescina.ro/, https://fillerina.ro/, https://cadu-crex.ro/

Our strategic partnership with Pierre Fabre Group in Romania started back in 1997 when Klorane, Galenic and Ducray entered the market. That was the start point of dermo-cosmetic category in pharmacies. 

In 2020 Pierre Fabre Dermo-Cosmetique is the leading* producer of dermo-cosmetic category in Romania. At this point we are present in this market with 7 brands: Eau Thermale Avene No.1* brand in dermo-cosmetic market , Laboratoires Klorane, Ducray, Galenic, A-derma, Elancyl and Rene Furterer.

In 2008 Pierre Fabre Oral Care entered Romanian pharmacy market with a complete portfolio for oral hygiene and care for daily use and treatment.

The story of Pierre Fabre Laboratories began in 1951 with a small-town pharmacy. Mr. Pierre Fabre embarked on an endeavor to develop plant-based products – drugs, family healthcare solutions and dermo-cosmetic products, all derived from the plant kingdom. 

Inventor of dermo-cosmetics almost 60 years ago, he created and developed dermo-cosmetic care products with high added value, acting to simultaneously promote the health and beauty of the skin and hair.

The Pierre Fabre Group is simultaneously a botanist, a grower and a manufacturer for its brands (A-Derma, Ducray, Eau Thermale Avène, Elancyl, Galénic, Klorane, René Furterer).

This original position within the cosmetics industry means that they can control the product life cycle, from the plant to the skin and the hair, whether healthy or damaged.

With 6 research centers in France and more than 300 dermo-cosmetics research experts, the Group identifies new targets, develops new natural extracts and designs new textures.

The Pierre Fabre Group has developed a knowledge and expertise chain which lets us control all the steps involved in the product design of our dermo-cosmetics brands.

The end-to-end dermo-cosmetics design process revolves around four combined skills to guarantee the reliability and effectiveness of our products: the identification of plant-based and biotechnological active, ingredients, formulation, packaging, efficacy and safety tests.

Innovation milestones 

In 2009, after more than 10 years of research and development, the Pierre Fabre Group perfected the D.E.F.I (Device for Exclusive Formula Integrity) packaging innovation for sterile cosmetics.

D.E.F.I is the first patented closure system that protects sterile formulas from all microorganisms. A packaging innovation still commended in 2018 with the award of 2 packaging Oscars.

The development process is based on a pharmaceutical culture and our dermo-cosmetic care products are not exempt from the fundamental rules of medical and pharmaceutical rigor which require that nothing is claimed without having been proven.

To guarantee that all our formulas are safe and harmless, we perform particularly stringent tests, beyond what is required by European legislation: in vitro pre-clinical tests, in vivo clinical tolerance tests

Every year, more than 1,000 tests and clinical studies are conducted in humans.

2013

Xéracalm A.D., an innovation derived from Thermal Spring Water

Pierre Fabre joined forces with the Oceanological Observatory in Banyuls to explore the composition of Avène spring water. They discovered a unique microflora: Aqua dolomiae. Researchers managed to turn it into an active ingredient with exceptional soothing properties - the future signature ingredient of the XéraCalm A.D. range to relieve itching caused by dry skin.

2014

Hemangiol, a dermatology innovation for infants

At the university hospital in Bordeaux, Dr. Christine Labrèze observed a spectacular improvement in the cutaneous vascular proliferative lesions of an infant treated with Propranolol for a heart problem. In response to the hospital’s request, Pierre Fabre created a pediatric version of Propranolol and conducted a vast clinical study to confirm its efficacy. Hemangiol was launched in 2014.

The Pierre Fabre Laboratoires purpose is drawing relentless inspiration from nature and plants, and by placing pharmaceutical ethics at the very heart of our operations.

Every time we care for a single person, we make the whole world better.

*Smart Data Research Value in Romania. Jan-Dec 2019

LYSASKIN is a French Dermo-Cosmetic Laboratory whose vocation is to research and develop product innovations to relieve skin problems. 

Our partnership with LYSASKIN started in 2013.

http://www.magnifiqueskin.ro/

Mylan is one of the top pharmaceutical companies in the world. Our strategic partnership with Mylan started back in 2015 in Romania. The product that entered in Romanian market in 2015 is Cystistat. 

https://www.cystistat.ro/

Omikron is an Italian company, specialized in products dedicated to ophthalmology. The products are modern, innovative (International patent holder for citicoline in ophthalmic solution) with many published clinical studies. Our partnership with Omikron Italia started last year, in 2019, concurrent with the start of Magna Ophta divizion. First three products from Omikron are OMK1, OMK2 and Neukron Ofta mese. 

https://www.omikronitalia.it/

Rominko was established as a trading company, in Bucharest in 1991. We started our partnership with Rominko back in 2012 with two products. 

PLACEHOLDER

The contract in Romania was signed in 2010, with effective starting date January 1st, 2011. During the fruitful years of partnership, both parties played an important role to increase the performance. In 2020, UCB has 3 products in MagnaPharm portfolio --> Xyzal Tabs, Xzyzal Dropsa and Zyrtec Drops.

https://www.ucb.com/worldwide/romania

Launched in Romania in October 2017 at the National Dermatology Congress, in front of almost 800 doctors who were delighted and gave positive feedback. Since January 2018, we have been working to implement prevention mindset, and now we are proud to announce that we have managed to keep away a lot of people from pain and the brand is similar to motto: "It doesn’t have to hurt”.

In May 2019 our company become in charge of TEVA Romania's Comercial Business, that includes CNS & Rheumatology portfolio with 2 market leader products in Romania, Azilect and Levodopa/Carbidopa/Entacapone, Namaxir for rheumatoid arthritis, Myocet for breast cancer, Emtricitabine/ Tenofovir Disoproxil for HIV and DuoResp & Gregal for Chronic Obstructive Pulmonary Disease.

Teva Pharmaceuticals Industries Ltd. is one of the most important pharmaceutical company worlwide and has the largest portfolio of generic and innovative products in the world. 

Magna's Ophthalmology second producer, NTC, focuses on developing novel pharmaceuticals in ophthalmology through innovative thinking and technology, with care for people. NTC is focused on research and development: over 30 development projects in ophthalmology, of which 10 are pharmaceutical products. The first product entring our portfolio is: Vitreonorm, Ededay & Edenight will follow soon.

https://www.ntcpharma.com/

Magna's Ophthalmology third producer, VISUfarma is a pharmaceutical company specialized in ophthalmology, with a clear mission: to bring global innovation in European ophthalmology. Their mission is to make a visible difference to eye health throughout Europe. VISUfarma is bringging to Romania the Xailin range (Xailin Fresh, Xailin Hydrate, Xailin HA, Xailin Gel, Xailin Night), VISUXL and hope more to come 

https://www.visufarma.com/

Pierre Fabre Group makes oncology a major priority. From the launch of a chemotherapy product derived from the Madagascar periwinkle in the late 1980s, to the development of it's “oral” form Navelbine Oral.

MagnaPharm team has been managing PFM Oncology portfolio for the last 5 years, proving impressive growth results for a mature product like Navelbine Oral.

https://www.pierre-fabre.com/en

Laboratoires Pierre Fabre is a French multinational pharmaceutical and cosmetics company.

"We are developing the drugs and care of tomorrow with the inexhaustible resources of our imaginations" Pierre Fabre. 

Our strategic partnership with Pierre Fabre Medicament started in 2014 with Cyclo 3 Fort, Tardyferon Fol & Tardyferon. In 2017, Osteogenon joined our portfolio.